Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients ...

ATRN-119 is the first and only macrocyclic ATR inhibitor in the clinic, with best in class potential

Related Keywords

Pennsylvania ,United States ,Nadeemq Mirza ,Mike Moyer ,Safety Review Committee ,Nasdaq ,Exchange Commission ,Aprea Therapeutics Inc ,Securities Exchange ,Chief Medical Officer ,Securities Act ,Securities Exchange Act ,Financial Condition ,